Lexaria’s Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study

The latest update is out from Lexaria Bioscience ( (LEXX) ).

Lexaria reported positive final results from its Human Pilot Study #5, which tested its DehydraTECH-liraglutide (DHT-LIR) oral capsules against injected Saxenda-branded liraglutide. The study met its primary endpoint of safety and tolerability, showing a 22.7% reduction in adverse events overall, including a 67% decrease in nausea and a 31% decline in gastrointestinal side effects, while functional outcomes such as blood glucose, insulin, and short-term weight changes were broadly comparable between the oral and injected formulations despite the oral dose being conservatively low. Although technical issues limited precise pharmacokinetic measurements, Lexaria observed similar temporal signal patterns between the two treatments and now sees a viable path to pursue what it believes could be the world’s first oral liraglutide product, potentially enabling use of the FDA’s 505(b)(2) regulatory pathway and strengthening its position in the competitive GLP-1 obesity and diabetes treatment market.

The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp., based in Kelowna, British Columbia, is a drug-delivery technology company focused on its patented DehydraTECH platform, designed to improve the delivery, tolerability and performance of existing active pharmaceutical ingredients. The company targets high-value therapeutic categories, including metabolic and cardiovascular diseases, by developing alternative oral formulations to replace or complement injectable drugs.

Average Trading Volume: 623,434

Technical Sentiment Signal: Sell

Current Market Cap: $18.04M

For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.